News and communications

/News and communications
The Del Bono family, founder of Mediolanum Farmaceutici, chooses Ardian as a strategic partner to consolidate its presence in Italy and to grow internationally.
Ardian acquires the majority of Neopharmed Gentili, a subsidiary of Mediolanum Farmaceutici
 
  • Mediolanum Farmaceutici will retain a minority stake in Neopharmed Gentili.
  • Neopharmed Gentili’s goal is to become an increasingly competitive actor in the pharmaceutical industry, oriented towards growth, international expansion and the creation of value.

Milan, 28 November 2018 – Mediolanum Farmaceutici, a pharmaceutical company founded in 1972 by the Del Bono family and now one of the main actors in the Italian market, particularly in the treatment of diseases in the cardiovascular area, has chosen Ardian, a leading global private equity firm, as their strategic partner to continue pursuing the national and international growth plan of its subsidiary Neopharmed Gentili.

Under the agreement, Mediolanum Farmaceutici remains a partner of Neopharmed Gentili with a minority shareholding, while Alessandro Del Bono will act as Chairman and Managing Director of the Company, which has its headquarters in Milan.

Neopharmed Gentili S.p.A. is the joint venture of the companies of the Mediolanum Farmaceutici Group dedicated to the development, production and marketing of solutions with high therapeutic value in the areas of vascular, cardio-metabolic, respiratory, antibiotic and over-the-counter drugs in Italy.

In 2017, through its strong sales network that stands out for its widespread coverage and quality, and thanks to a significant knowledge of the sector and long-lasting relationships built within it, Neopharmed Gentili registered sales for 192 million euros in a sector in which the company is a well-recognized pharmaceutical brand, especially in some specialist therapeutic areas, as well as being chosen by large pharmaceutical companies as a reliable and specialized partner (e.g. the consolidated partnership with Merck and Teva for the distribution of some licensed products).

The acquisition plan implemented by Neopharmed Gentili up until today has allowed the company to significantly increase its market share, its product portfolio, and to strengthen its top-line, while also expanding its share of intellectual property products.

Alessandro Del Bono, president and CEO of Neopharmed Gentili, said: Neopharmed Gentili’s goal is to become an increasingly competitive actor in the pharmaceutical industry, oriented towards growth, international expansion and the creation of value. We have decided to share this project with Ardian, the leading private equity firm in Europe and the third largest in the world. This move will allow the company to accelerate its development and aim for new acquisitions, strengthening its presence in strategic areas of the pharmaceutical sector, and, last but not least, to protect employment in Italy.

Nicolò Saidelli, Managing Director and head of Ardian in Italy, said: “We are proud that the Del Bono family has chosen Ardian as their partner for the development of Neopharmed Gentili, which is an example of Italian entrepreneurial excellence with strong growth opportunities. Today, Neopharmed Gentili enjoys widely well-regarded in the Italian pharmaceutical industry and is ready to undertake a path of international expansion through collaborations with leading global players, such as Merck and Teva Pharmaceutical. We are glad to be working together with the Del Bono family in this new challenge; we will work with passion, thanks to the experience and skills that characterise Ardian, and to the many development projects we have previously followed in Italy, with entrepreneurs and managers guiding family businesses”.

ARDIAN Advisor
M&A Advisor
: Rothschild & Co.
Commercial Due Diligence: Bain – Valerio di Filippo
Financial Due Diligence: PWC – Emanuela Pettenò
Tax: Gitti & Partners – Diego De Francesco, Paolo Ferrandi
Legal: Giovannelli e Associati – Alessandro Giovannelli, Fabrizio Scaparro
Finance: Gattai, Minoli, Agostinelli & Partners – Lorenzo Vernetti

MEDIOLANUM FARMACEUTICI Advisor
M&A Advisor
: Four Partners – Guido Tugnoli, Pietro Pagnozzi, Angela Celetti
Legal Advisor NCTM – Pietro Zanoni

Mediolanum Farmaceutici S.p.A.
Mediolanum Farmaceutici is an Italian pharmaceutical group founded in Milan in 1972. Over the years, the Group has strengthened its presence in Italy and has grown to become an international reality. The research and development of original and innovative products is an integral and fundamental part of the Group’s activity, which has completed the clinical development of four products over the years, obtaining over 700 patents for more than 40 countries. Mediolanum Farmaceutici is known as a serious and dynamic company, which believes in promoting a culture of Corporate Social Responsibility in order to provide a service to the community.
For further information, visit www.mediolanum-farma.it

Neopharmed Gentili S.p.A.
Neopharmed Gentili is an Italian pharmaceutical group founded in 2011 in Milan following the merge of two prestigious companies, Gentili Srl, acquired in 2009, and Neopharmed Srl, acquired in 2010. Today, Neopharmed Gentili is one of the most important actors in the Italian pharmaceutical market. Throughout the years, the Company has developed through external growth, thanks to a series of partnerships and acquisitions which have contributed to strengthen its product portfolio and its presence in key therapeutic areas. In particular, in 2017, the Group acquired the Italian subsidiary of Belgian company Therabel Gienne Pharma and entered into a partnership with Teva Pharmaceuticals for the promotion and development of medicines for the treatment of respiratory diseases.
Neopharmed Gentili is currently engaged in researching, testing, manufacturing and distributing drugs in many therapeutic areas: from vascular to cardio-metabolic treatments, from drugs against respiratory diseases to antibiotics, over-the-counter drugs and supplements.
For further information, visit www.neogen.it

ARDIAN
Ardian is a leading global private investment firm managing or consulting for a total of $82 billion in Europe, the Americas, and Asia. The company, the majority of which is owned by its employees, is driven by an entrepreneurial spirit and focused on generating excellent performance for its global investors.
Through its philosophy of sharing results with all stakeholders, Ardian’s business boosts individual, corporate and economic growth worldwide.
Inspired by its core values of excellence, loyalty and entrepreneurship, Ardian has a global network of over 550 employees spread across 14 locations in Europe (Frankfurt, Jersey, London, Luxembourg, Madrid, Milan, Paris and Zurich), the Americas (New York, San Francisco and Santiago) and Asia (Beijing, Singapore and Tokyo). The company manages funds on behalf of its 750 or so investors across five investment areas in which it has extensive experience: Funds of Funds, Direct Funds, Infrastructure, Real Estate and Private Debt.
Follow Ardian on Twitter @Ardian
www.ardian.com

For further information:

Neopharmed Gentili S.p.A.
Ottavia Landi di Chiavenna
Director of External Relations and Institutional Affairs
o.landi@neogen.it
+39.342.3409572
+39 06.94354560

Mediolanum Farmaceutici Press Enquiries
Value Relations
Angela Del Giudice
a.delgiudice@vrelations.it
+39.392.6858392
Domenica Donato
d.donato@vrelations.it
+39.320.9547481
+39.06.6788870

Ardian Press Enquiries
Image Building
Cristina Fossati, Luisella Murtas, Anna Pirtali
+39 02 89011300
ardian@imagebuilding.it